Other substances

Epoprostenol

A prostacyclin.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Used to treat other disease

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

Epoprostenol on PubChem

Marketed as

CARIPUL; EPOPROSTENOL; FLOLAN; VELETRI

CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1C/C(=C/CCCC(=O)O)/O2)O)O

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Superiority of cilostazol among antiplatelet FDA‐approved drugs against COVID 19 Mpro and spike protein: Drug repurposing approach Spike protein 3CLpro Small molecule In silico Screening	in silico	1.90	Predicted to inhibit the SARS-CoV-2 spike protein.	Sep/27/2020

AI-suggested references

Link	Publication date
Evaluation of Continuous Inhaled Epoprostenol in the Treatment of Acute Respiratory Distress Syndrome, Including Patients With SARS-CoV-2 Infection.	Jan/13/2022
Investigacion cientifica prioritaria en Latinoamerica para orientar la prevencion y el control de la COVID-19	Sep/16/2021
Brief Report: Rapid Clinical Recovery From Critical Coronavirus Disease 2019 With Respiratory Failure in a Pregnant Patient Treated With IV Vasoactive Intestinal Peptide	Jul/08/2021
Responsiveness of Inhaled Epoprostenol in Respiratory Failure due to COVID-19	Sep/24/2021
Evaluation of aerosolized epoprostenol for hypoxemia in non-intubated patients with coronavirus disease 2019	Jan/11/2021
STEMI associated with SARS-CoV-2 infection and the use of ECMO as a potential therapeutic approach in addition to the PCI.	Mar/08/2021
Effects of Inhaled Epoprostenol and Prone Positioning in Intubated Coronavirus Disease 2019 Patients With Refractory Hypoxemia.	Dec/16/2020
The Use of Inhaled Epoprostenol for Acute Respiratory Distress Syndrome Secondary Due To COVID-19: a Case Series	Nov/16/2021
Evaluation of the Efficacy and Safety of Inhaled Epoprostenol and Inhaled Nitric Oxide for Refractory Hypoxemia in Patients With Coronavirus Disease 2019	Oct/19/2020
Rescue therapy with thrombolysis in patients with severe COVID-19-associated acute respiratory distress syndrome	Feb/19/2021
Superiority of cilostazol among antiplatelet FDA-approved drugs against COVID 19 Mpro and spike protein: Drug repurposing approach	Jan/22/2021
Use of inhaled epoprostenol with high flow nasal oxygen in non-intubated patients with severe COVID-19	Feb/23/2022

Clinical trials

ID	Title	Status	Phase	Start date	Completion date
NCT04452669	VentaProst in Subjects With COVID-19 Requiring Mechanical Ventilation	Completed	Phase 2	Sep/15/2020	Jun/29/2021
Alternative id - APC-VPCOV-CLN-001 Interventions - Drug: VentaProst (inhaled epoprostenol delivered via a dedicated delivery system) Study type - Interventional Study results - No Results Available Locations - Ohio State University, Columbus, Ohio, United States Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 11 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Reduction in Respiratory Failure\|Reduction in Cardiac/Circulatory Failure\|Improvement in Oxygenation\|Improved Clinical Outcomes

Export (.csv)